Flag of the European Union EU Clinical Trials Register Help

Clinical trials for colon cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    765 result(s) found for: colon cancer. Displaying page 39 of 39.
    «« First « Previous 31  32  33  34  35  36  37  38  39 
    EudraCT Number: 2012-000305-76 Sponsor Protocol Number: CMEK162X2111 Start Date*: 2012-09-03
    Sponsor Name:Novartis Farmacéutica S.A.
    Full Title: A phase Ib/II open-label, multi-center study of the combination of MEK162 plus AMG 479 (ganitumab) in adult patients with selected advanced solid tumors
    Medical condition: colorectal adenocarcinoma. metastatic pancreatic adenocarcinoma melanoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033599 Pancreatic adenocarcinoma metastatic LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10053571 Melanoma LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052360 Colorectal adenocarcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Prematurely Ended) BE (Completed) FR (Completed) DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-002917-11 Sponsor Protocol Number: A0081124 Start Date*: 2006-11-02
    Sponsor Name:Pfizer Pharma GmbH
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF THE PREVENTION AND TREATMENT OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY SYMPTOMS WITH PREGABALIN IN SUBJECTS WITH ADVANCED COLORECTAL CANCER
    Medical condition: CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY SYMPTOMS
    Disease: Version SOC Term Classification Code Term Level
    8.1 10029331 Neuropathy peripheral LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000830-37 Sponsor Protocol Number: CP-4-005 Start Date*: 2013-07-03
    Sponsor Name:OPKO Biologics Ltd.
    Full Title: A Phase 3, Multicenter Study Designed to Evaluate the Efficacy and Safety of a Long Acting hGH Product (MOD-4023) in Adult Subjects with Growth Hormone Deficiency
    Medical condition: Adult or childhood onset growth hormone deficiency (GHD)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed) GR (Completed) GB (Completed) AT (Completed) ES (Prematurely Ended) NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-003622-29 Sponsor Protocol Number: BAYe4465/IMPACT12198 Start Date*: 2007-06-13
    Sponsor Name:Bayer AG
    Full Title: The ARRIVE Study (Aspirin to Reduce Risk of Initial Vascular Events) - A Randomized, Double-Blind, Placebo Controlled, Multicenter, Parallel Group Study to Assess the Efficacy (Reduction of Cardiov...
    Medical condition: Patients at moderate risk of CHD events (10-20% 10-year CHD risk; approximately 30% 10-year risk of CVD events based on the underlying assumption at study start).
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004852 10072760 Transient ischemic attack LLT
    19.0 100000004852 10042244 Stroke LLT
    19.0 10007541 - Cardiac disorders 10046251 Unstable angina LLT
    19.0 10007541 - Cardiac disorders 10028596 Myocardial infarction PT
    19.0 10018065 - General disorders and administration site conditions 10049993 Cardiac death PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) DE (Completed) IE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-001377-28 Sponsor Protocol Number: 27577 Start Date*: 2008-06-11
    Sponsor Name:Merck Serono International S.A.
    Full Title: Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of...
    Medical condition: Adult patients with moderate to severe chronic plaque psoriasis -- who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosp...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061664 Autoimmune disorder LLT
    9.1 10025139 Lupus erythematosus systemic LLT
    9.1 10047888 Wegener's granulomatosis LLT
    9.1 10002817 Antiphospholipid syndrome LLT
    9.1 10040767 Sjogren's syndrome LLT
    9.1 10039073 Rheumatoid arthritis LLT
    9.1 10028245 Multiple sclerosis LLT
    9.1 10045228 Type I diabetes mellitus LLT
    9.1 10011401 Crohn's disease LLT
    9.1 10009900 Colitis ulcerative LLT
    9.1 10003827 Autoimmune hepatitis LLT
    9.1 10049046 Autoimmune thyroiditis LLT
    9.1 10003822 Autoimmune haemolytic anaemia NOS LLT
    9.1 10034697 Pernicious anemia LLT
    9.1 10028417 Myasthenia gravis LLT
    9.1 10018620 Goodpasture's syndrome LLT
    9.1 10018766 Guillain Barre syndrome LLT
    9.1 10043554 Thrombocytopenia LLT
    9.1 10037153 Psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Prematurely Ended) AT (Prematurely Ended) NL (Prematurely Ended) PT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 31  32  33  34  35  36  37  38  39 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jul 18 07:01:09 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA